Pharmafile Logo
Pharmafocus logo
Advanced Search

idarucizumab

Showing 4 posts of 4 posts found.

BI building at night

FDA approves Boehringer’s Pradaxa reversal agent

October 19, 2015
Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …

News
Boehringer image

Boehringer scores trial success for Pradaxa antidote

June 29, 2015
Research and Development, Sales and Marketing Boehringer, Pradaxa, idarucizumab

Bosses at Boehringer Ingelheim say the latest results of a study of idarucizumab, and antidote for its blockbuster blood-thinner Pradaxa, …

News
Boehringer image

Boehringer chases approval for anti-Pradaxa drug

March 3, 2015
Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab

Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …

News
Boehringer image

Boehringer trials Pradaxa anti-bleeding antidote

December 11, 2014
Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab

Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025